Emmes Secures Major NIH Contract to Lead Clinical Coordinating Center for National Institute on Drug Abuse Trials

Emmes, part of Emmes Group, announced they will provide a Clinical Coordinating Center for the NIH's National Institute on Drug Abuse Clinical Trials &nbs...

September 26, 2024 | Thursday | News
Eli Lilly CEO David Ricks Announces Major Expansion of India Research Hub, Poised to Transform Global Drug Innovation

Eli Lilly and Company (NYSE: LLY), a global leader in biopharmaceuticals, has announced plans to expand its research and development (R&D) center in ...

September 24, 2024 | Tuesday | News
Nxera Pharma Secures Japanese Approval for QUVIVIQ™ to Treat Insomnia Based on Positive Phase 3 Trial Results

The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3...

September 24, 2024 | Tuesday | News
Thermo Fisher's PPD Clinical Research Expands to GoCo Health Innovation City in Sweden

The PPD clinical research business joins GoCo Health Innovation City in Gothenburg, Sweden The PPD™ clinical research business of Thermo Fisher Sc...

September 19, 2024 | Thursday | News
Vidac Pharma Secures Broad U.S. Patent for Pioneering Cancer Treatment Mode of Action

Vidac Pharma Holdings Plc., a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments,  announces that the U...

September 19, 2024 | Thursday | News
BeiGene Secures Israeli Ministry of Health Approval for TEVIMBRA® in Treating Esophageal Squamous Cell Carcinoma

BeiGene, a global oncology company, announced that the Israeli Ministry of Health (IL MOH) has approved TEVIMBRA® (tislelizumab) as monotherapy for t...

September 18, 2024 | Wednesday | News
Immutep Presents Promising Phase IIb Trial Results of Efti and KEYTRUDA® at ESMO 2024

Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024 In patients with any PD-L1 expression (CPS ≥1), efti in co...

September 17, 2024 | Tuesday | News
MaxCyte and Kamau Therapeutics Partner to Advance Next-Gen Gene Therapies for Sickle Cell Disease

MaxCyte, Inc.,  a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and comme...

September 16, 2024 | Monday | News
CPC Introduces Innovative Aseptic Micro-Connector for Cell and Gene Therapy Freeze Cassettes

CPC (Colder Products Company), part of Dover  and a leading manufacturer of connection technologies used in biopharmaceutical processing, today...

September 12, 2024 | Thursday | News
Symbiosis Pharmaceutical Expands Manufacturing Capacity with New Facility in Stirling

Symbiosis Pharmaceutical Services Ltd (Symbiosis), a rapidly growing sterile biopharmaceutical Contract Manufacturing Organisation (CMO) announces the pu...

September 09, 2024 | Monday | News
Scantox Group Acquires UK-Based Gentronix to Expand Genetic Toxicology Services

Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Resear...

September 09, 2024 | Monday | News
Valneva and Pfizer Report Positive Phase 2 Results for Lyme Disease Vaccine Candidate, VLA15, Following Second Booster Dose

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. (NYSE: PFE) today announced positive results from the VLA15-221 Phase 2 study of t...

September 03, 2024 | Tuesday | News
Sanofi’s Tolebrutinib Shows First Disability Reduction in Phase 3 nrSPMS Study

Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary...

September 02, 2024 | Monday | News
HUTCHMED Voluntarily Withdraws Supplemental NDA for Fruquintinib in China, Cites Need for Further Evaluation in Gastric Cancer Treatment

HUTCHMED announces that it has voluntarily withdrawn its supplemental New Drug Application (“NDA”) in China for fruquintinib in combination w...

August 30, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close